Company intelligence / Profile preview
Overland Therapeutics
South San Francisco, California, United Statesoverlandtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program OL-101 (bispecific CAR-T targeting GPRC5D and BCMA) is in Phase 1. Company also has off-the-shelf allogeneic gamma delta CAR-T programs for autoimmune disorders and oncology. Several other cell therapy programs are in clinical or preclinical stages.[1][2]
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR-T cell therapyBispecific monoclonal antibodyCell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Allogene TherapeuticsOverland Pharmaceuticals
Beyond the preview
Go deeper on Overland Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Overland Therapeutics.